Mediwelcome Healthcare Management & Technology Inc. (2159) AI Stock Analysis

• Market Cap: HK$88.00M
• Dividend Yield: N/A
• Average Volume (3M): 29.63K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.80
• Revenue Growth: -4.57%
• EPS Growth: 52.37%
• Country: HK
• Employees: 311
• Sector: Healthcare
• Sector Strength: 59
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -0.25
• Shares Outstanding: 200,000,000
• 10 Day Avg. Volume: 51,040
• 30 Day Avg. Volume: 29,626
• PEG Ratio: -0.04
• Price to Book (P/B): 1.08
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -13.68
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 46 Neutral
• Price Target: ―

Mediwelcome Healthcare Management & Technology Inc. faces significant challenges with declining revenues, persistent losses, and cash flow issues, resulting in a low financial performance score. Technical indicators suggest cautious sentiment, with mixed signals and potential oversold conditions. The negative valuation metrics further underscore the financial instability, warranting a conservative outlook on the stock until meaningful improvements are realized.

Mediwelcome Healthcare Management & Technology Inc. Business Overview & Revenue Model

Company Description

Mediwelcome Healthcare Management & Technology Inc. (2159) is a company operating within the healthcare sector, primarily focusing on providing comprehensive healthcare management services and technological solutions. The company specializes in offering medical conference services, continuing medical education, and hospital management consulting. By leveraging advanced technology, Mediwelcome aims to enhance healthcare delivery and management efficiency.

How the Company Makes Money

Mediwelcome Healthcare Management & Technology Inc. generates revenue through multiple streams within the healthcare industry. The primary revenue sources include organizing medical conferences and events, which attract healthcare professionals and industry stakeholders, generating income through participation fees and sponsorships. Additionally, the company offers continuing medical education programs, providing valuable training and development for healthcare professionals, thus earning revenue through course fees and partnerships with educational institutions. Mediwelcome also provides hospital management consulting services, assisting healthcare facilities in optimizing their operations and improving patient care, charging fees for their consulting expertise. Strategic partnerships with hospitals, pharmaceutical companies, and educational entities further bolster their revenue streams, allowing the company to expand its service offerings and market reach.

Mediwelcome Healthcare Management & Technology Inc. Financial Statement Overview

Summary

Mediwelcome Healthcare Management & Technology Inc. faces financial challenges with declining revenues and persistent losses. While there are some positive signs in cost management and moderate leverage, the company's cash flow issues and decreasing equity base present significant risks. Continued operational improvements and strategic adjustments are necessary for financial stability.

Income Statement

The company's revenue has been declining, with a significant drop from 2021 to 2024. The EBIT and net income margins are negative, indicating operational challenges and losses. However, there is a slight improvement in gross profit margin from 2023 to 2024, suggesting some cost management progress.

Balance Sheet

The company has maintained positive stockholders' equity, though it has declined over recent years. The debt-to-equity ratio remains moderate, showing some leverage but not excessively risky. The equity ratio is decreasing, indicating lower asset financing through equity, which could pose a risk if liabilities increase.

Cash Flow

The company struggles with cash flow, with negative operating and free cash flows in recent years. The operating cash flow to net income ratio is not meaningful due to negative values, presenting challenges in cash generation. Although there was a significant capital expenditure reduction, it wasn't enough to offset cash flow deficits.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
321.56M	331.31M	323.37M	708.36M	432.29M
	Gross Profit
51.00M	29.89M	32.55M	93.60M	96.31M
	EBIT
-36.21M	-81.92M	-87.64M	-1.78M	23.35M
	EBITDA
-33.61M	-74.53M	-69.08M	17.72M	41.06M
	Net Income Common Stockholders
-45.24M	-94.10M	-93.74M	4.64M	21.04M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
71.66M	80.35M	154.02M	174.83M	104.89M
	Total Assets
194.09M	214.32M	317.83M	366.70M	280.08M
	Total Debt
47.73M	31.13M	26.48M	25.18M	25.43M
	Net Debt
-23.93M	-49.22M	-112.09M	-140.15M	-63.56M
	Total Liabilities
120.81M	94.35M	116.97M	73.21M	109.08M
	Stockholders Equity
71.14M	116.13M	195.02M	283.11M	161.18M
Cash Flow		Free Cash Flow
0.00	-77.18M	-22.75M	-24.73M	17.31M
	Operating Cash Flow
0.00	-75.58M	-18.46M	262.00K	31.12M
	Investing Cash Flow
0.00	16.46M	-8.36M	-16.77M	-10.98M
	Financing Cash Flow
0.00	906.00K	54.00K	92.84M	-4.79M

Mediwelcome Healthcare Management & Technology Inc. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.44
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2159, the sentiment is Negative. The current price of 0.44 is below the 20-day moving average (MA) of 0.45, below the 50-day MA of 0.45, and above the 200-day MA of 0.43, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 45.79 is Neutral, neither overbought nor oversold. The STOCH value of 46.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2159.

Mediwelcome Healthcare Management & Technology Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1513	74 Outperform	HK$34.08B	12.80	14.56%	3.79%	-5.37%	6.28%
8606	62 Neutral	HK$195.19M	―	-6.08%	―	8.50%	67.35%
Sector *	54 Neutral	$5.38B	3.27	-45.10%	3.30%	16.81%	0.02%
1503	49 Neutral	€1.38B	―	-5.63%	9.18%	3.93%	-5.97%
2159	46 Neutral	HK$88.00M	―	-48.20%	―	-4.57%	52.37%
1429	44 Neutral	HK$96.00M	―	-14.47%	―	-4.16%	-643.18%

Mediwelcome Healthcare Management & Technology Inc. Corporate Events

Mediwelcome Announces Annual General Meeting with Key Resolutions

Mediwelcome Healthcare Management & Technology Inc. has announced its upcoming annual general meeting scheduled for June 25, 2025, in Beijing. The meeting will address several key resolutions, including the re-election of directors, the re-appointment of the company’s auditor, and the approval of a general mandate for the directors to issue additional shares. These resolutions are aimed at strengthening the company’s governance and operational capabilities, potentially impacting its market position and shareholder value.

Mediwelcome Enhances Governance with New Nomination Committee

Mediwelcome Healthcare Management & Technology Inc. has established a Nomination Committee to enhance its corporate governance structure. The committee, primarily composed of independent non-executive directors, is tasked with reviewing the board’s composition and recommending qualified candidates for directorships. This move is expected to strengthen the company’s strategic alignment and ensure diversity and expertise within its leadership.

Mediwelcome Reports 2024 Annual Results with Notable Losses

Mediwelcome Healthcare Management & Technology Inc. reported its annual results for the year ended December 31, 2024, showing a decrease in revenue from RMB 331,308,000 in 2023 to RMB 321,558,000 in 2024. Despite a reduction in administrative and research expenses, the company experienced a comprehensive loss of RMB 46,688,000 for the year, attributed to various factors including impairment losses and a decline in other income.

Mediwelcome Announces Board Composition and Roles

Mediwelcome Healthcare Management & Technology Inc. has announced the composition of its board of directors and the roles they will undertake within the company. This announcement is significant as it outlines the leadership structure and committee assignments, which are crucial for the company’s strategic direction and governance.

Mediwelcome Schedules Board Meeting to Approve Annual Results

Mediwelcome Healthcare Management & Technology Inc. has scheduled a board meeting for March 26, 2025, to review and approve the annual results for the year ending December 31, 2024. The meeting will also consider the recommendation for a final dividend and address other business matters, potentially impacting the company’s financial strategy and shareholder returns.